Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Biosckin Molecular & Cell Therapies S A currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is limited to 1 distinct examiner and 1 distinct art unit, showing a concentrated prosecution profile. The 1 pending office action represents the entirety of the company's current interaction with the patent office in this sector. The focus within 1 distinct art unit indicates that the molecular or cell therapy technology is being evaluated within a specific specialized group.
PURDY, KYLE A is the busiest examiner, with 1 busiest examiner pending action. Since 1 distinct examiner, PURDY, KYLE A, is handling the case, the applicant's strategy should be tailored to his specific history and preferences. Practitioners should research the examiner's typical approach to biotechnology claims to better navigate the 1 pending office action. The involvement of 1 distinct examiner and 1 distinct art unit minimizes the complexity of the prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PURDY, KYLE A | 1 | 40.9% | +35.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17911435 | METHOD FOR PRODUCING HYDROXYAPATITE-BIOGLASS MATERIALS, SAID MATERIALS AND PRODUCTS THEREOF | PURDY, KYLE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17911435 | METHOD FOR PRODUCING HYDROXYAPATITE-BIOGLASS MATERIALS, SAID MATERIALS AND PRODUCTS THEREOF | PURDY, KYLE A | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17911435 | METHOD FOR PRODUCING HYDROXYAPATITE-BIOGLASS MATERIALS, SAID MATERIALS AND PRODUCTS THEREOF | PURDY, KYLE A | 1611 | §103§112 | Non-Final OA | — | Pending | Sep 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiosckin Molecular & Cell Therapies S A has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Kyle A Purdy has the most, with 1 of Biosckin Molecular & Cell Therapies S A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.